Apr 19 |
Zai Lab files automatic ordinary shares offering
|
Apr 16 |
A Risky Bet: Zai Lab's Uncertain Future
|
Apr 15 |
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
|
Apr 11 |
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
|
Apr 2 |
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
|
Apr 1 |
Shareholders in Zai Lab (NASDAQ:ZLAB) are in the red if they invested three years ago
|
Apr 1 |
Zai Lab reports Krazati lung cancer study meets primary endpoint
|
Apr 1 |
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
|
Mar 27 |
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
|
Mar 27 |
Novocure climbs after late-stage win for lung cancer therapy
|